Artwork
iconShare
 
Manage episode 486579932 series 2797294
Content provided by Informa TechTarget. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Informa TechTarget or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.

Featuring: Sara Heath, executive editor, Xtelligent Healthcare

Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare

In today’s episode, we’ll cover…

  • The end of GLP-1 compounding creates a significant access barrier for millions of patients seeking weight management solutions
  • Financial inequity deepens as patients transition from affordable compounded options to expensive branded medications
  • Future innovation in oral GLP-1 formulations offers hope but remains constrained by long-term patent protections

and more!

References:

To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.
To watch the video clips of our podcast, subscribe to our YouTube channel, @HealthcareStrategies.

  continue reading

122 episodes